MX2022012610A - Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. - Google Patents
Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.Info
- Publication number
- MX2022012610A MX2022012610A MX2022012610A MX2022012610A MX2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A
- Authority
- MX
- Mexico
- Prior art keywords
- fedratinib
- methods
- treating anemia
- ligand trap
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 title abstract 2
- 208000007502 anemia Diseases 0.000 title abstract 2
- 229950003487 fedratinib Drugs 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title 1
- 102100027647 Activin receptor type-2B Human genes 0.000 abstract 2
- 108010057453 activin receptor type II-B Proteins 0.000 abstract 2
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009400P | 2020-04-13 | 2020-04-13 | |
| PCT/US2021/026816 WO2021211418A1 (en) | 2020-04-13 | 2021-04-12 | Methods for treating anemia using an actriib ligand trap and fedratinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012610A true MX2022012610A (es) | 2022-11-07 |
Family
ID=78085002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012610A MX2022012610A (es) | 2020-04-13 | 2021-04-12 | Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181690A1 (https=) |
| EP (1) | EP4135736A4 (https=) |
| JP (1) | JP2023523568A (https=) |
| KR (1) | KR20230003502A (https=) |
| CN (1) | CN115427056A (https=) |
| AU (1) | AU2021256419A1 (https=) |
| BR (1) | BR112022020628A2 (https=) |
| IL (1) | IL297258A (https=) |
| MX (1) | MX2022012610A (https=) |
| WO (1) | WO2021211418A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| PT3286206T (pt) * | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| CN107847562A (zh) * | 2015-05-13 | 2018-03-27 | 细胞基因公司 | 使用 ACTRII 配体陷阱治疗 β‑地中海贫血 |
| PL3490582T3 (pl) * | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| WO2018053142A2 (en) * | 2016-09-14 | 2018-03-22 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| HRP20241477T1 (hr) * | 2017-06-14 | 2025-01-03 | Celgene Corporation | Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom |
| KR20210047308A (ko) * | 2018-08-21 | 2021-04-29 | 시에라 온코로지, 인코퍼레이티드 | 골수섬유증을 치료하는 혈소판 수-불특정 방법 |
| EP3856189A4 (en) * | 2018-09-25 | 2022-06-29 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
-
2021
- 2021-04-12 WO PCT/US2021/026816 patent/WO2021211418A1/en not_active Ceased
- 2021-04-12 JP JP2022562528A patent/JP2023523568A/ja active Pending
- 2021-04-12 BR BR112022020628A patent/BR112022020628A2/pt unknown
- 2021-04-12 EP EP21787716.6A patent/EP4135736A4/en active Pending
- 2021-04-12 CN CN202180028593.0A patent/CN115427056A/zh active Pending
- 2021-04-12 IL IL297258A patent/IL297258A/en unknown
- 2021-04-12 US US17/995,915 patent/US20230181690A1/en active Pending
- 2021-04-12 KR KR1020227039230A patent/KR20230003502A/ko active Pending
- 2021-04-12 MX MX2022012610A patent/MX2022012610A/es unknown
- 2021-04-12 AU AU2021256419A patent/AU2021256419A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4135736A1 (en) | 2023-02-22 |
| JP2023523568A (ja) | 2023-06-06 |
| AU2021256419A1 (en) | 2022-10-20 |
| KR20230003502A (ko) | 2023-01-06 |
| IL297258A (en) | 2022-12-01 |
| WO2021211418A1 (en) | 2021-10-21 |
| EP4135736A4 (en) | 2024-06-26 |
| CN115427056A (zh) | 2022-12-02 |
| US20230181690A1 (en) | 2023-06-15 |
| BR112022020628A2 (pt) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012610A (es) | Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. | |
| Moulder et al. | Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation | |
| Cavaletti | Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know | |
| Xie et al. | Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer | |
| EA201590210A1 (ru) | Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| NZ601111A (en) | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies | |
| MX2016004411A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1). | |
| Sakata et al. | A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer | |
| ZA202204075B (en) | Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof | |
| Cotreau et al. | Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor | |
| Carlo‐Stella et al. | A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma | |
| Lu et al. | Model‐based meta‐analysis for quantifying Paclitaxel dose response in cancer patients | |
| Shukuya et al. | Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients | |
| MX2019004222A (es) | Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias. | |
| Banón et al. | Efficacy, safety, and lack of interactions with the use of raltegravir in HIV‐infected patients undergoing antineoplastic chemotherapy | |
| Inal et al. | Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study | |
| Forero-Torres et al. | Abstract CT056: Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies | |
| Esteban et al. | Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies | |
| Elishmereni et al. | IL-21 immunotherapy in solid cancers: Therapeutic insights from a preclinically validated mathematical pharmacokinetic and pharmacodynamics model | |
| Ackermann et al. | Abstract B09: Nintedanib inhibits tumor and vessel growth and leads to vascular normalization in A549-NSCLC-xenografts | |
| MX2025010617A (es) | Metodos para tratar la colitis ulcerosa | |
| Mecke et al. | Abstract CT042: Atezolizumab (atezo)+ platinum/gemcitabine (plt/gem) vs placebo+ plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130 | |
| Mortazavi et al. | Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer. |